Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery

Garnet BioTherapeutics

Status and phase

Completed

Phase 2

Conditions

Scar Formation

Treatments

Biological: Placebo

Biological: GBT009

Study type

Interventional

Funder types

Industry

Identifiers

NCT01053897

GBT-09-001

Details and patient eligibility

About

The primary objective of this study is to assess whether intradermal injections of GBT009 along full thickness incisions following surgery results in an improvement in scar appearance.

Enrollment

5 patients

Sex

Female

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Subjects must meet all of the following criteria to be considered eligible to participate in the study:

be a female between 18 and 70 years of age, inclusive
have a body mass index ≤ 32 kg/m2 and a body weight between 50 and 95 kg, inclusive
be scheduled for a mastectomy with breast reconstruction surgery using an abdominal flap technique
for women diagnosed with breast cancer, has standard of care treatment for breast cancer prior to surgery and will have standard of care treatment for breast cancer after surgery
for subjects of childbearing potential, be surgically sterile or using an insertable, injectable, transdermal, or combination oral contraceptive approved by the FDA through completion of the study and have negative results on a serum pregnancy test done before administration of study medication (women who are postmenopausal [no menses for at least 2 years] are also eligible to participate)
be able to understand the study procedures, agree to participate in the study program, and voluntarily provide written informed consent

Exclusion Criteria: Subjects who meet any of the following criteria will be excluded from participating in the study:

have clinically significant laboratory abnormalities at screening
have, as determined by the investigator or the sponsor's medical monitor, a history or clinical manifestations of significant renal, hepatic, cardiovascular, metabolic, neurologic, psychiatric, coagulopathic disorder or other condition that would preclude participation in the study
have received treatment for a severe, uncontrolled inflammatory disease or allergic condition within three months of screening
have a life expectancy ≤ 2 years
have a history of alcoholism or drug addiction or abuse within 5 years
have evidence of a clinically significant abnormality upon evaluation of 12 lead ECG
have evidence of any past or present clinically significant medical condition, including skin disease, that would impair wound healing
have a history of keloid scar formation
have existing scarring in the abdominal area of study that would interfere with the efficacy assessments
have a history of (within the past 5 years) or an active malignancy, other than breast cancer
have a breast cancer that has been staged at Stage IIIB, IIIC or IV
have received a cytotoxic agent or have been treated with radiation within 90 days of screening and/or, in the opinion of the investigator, will likely require treatment in the 30 day period following the administration of study medication
have received anticoagulation medication within 5 days of dosing with study medication
have participated in any study involving an investigational product within 30 days before dosing with study medication
have routinely used tobacco products within 6 months preceding the study period